Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcial Sebode

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
BMC Gastroenterology|October 17, 2020
Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case reportMaria Paparoupa, Henning Wege, Anna Creutzfeldt, et al.
Journal of Hepatology|July 25, 2020
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis GroupAnsgar W Lohse, Marcial Sebode, Marianne H Jørgensen, et al.
United European Gastroenterology Journal|June 9, 2021
Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online surveyBritta Franziska Zecher, Gustav Buescher, José Willemse, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 28, 2017
Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune HepatitisMoritz Peiseler, Tina Liebscher, Marcial Sebode, et al.
Journal of Hepatology|December 3, 2014
Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitisJohannes Hartl, Hanno Ehlken, Christina Weiler-Normann, et al.
Der Internist|September 21, 2021
[Severe secondary sclerosing cholangitis as manifestation of a very rare underlying disease]Britta Franziska Zecher, Roman Zenouzi, Melanie Lang, et al.
Journal of Hepatology|November 29, 2017
Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitisJohannes Hartl, Hanno Ehlken, Marcial Sebode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcomeMartin Reike-Kunze, Roman Zenouzi, Johannes Hartel, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2020
A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitisTimur Liwinski, Christian Casar, Malte C Ruehlemann, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
<i>Quo vadis</i> autoimmune hepatitis? - Summary of the 5<sup>th</sup> international autoimmune hepatitis group research workshop 2024Bastian Engel, David N Assis, Mamatha Bhat, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
BMC Gastroenterology|October 17, 2020
Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case reportMaria Paparoupa, Henning Wege, Anna Creutzfeldt, et al.
Journal of Hepatology|July 25, 2020
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis GroupAnsgar W Lohse, Marcial Sebode, Marianne H Jørgensen, et al.
United European Gastroenterology Journal|June 9, 2021
Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online surveyBritta Franziska Zecher, Gustav Buescher, José Willemse, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 28, 2017
Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune HepatitisMoritz Peiseler, Tina Liebscher, Marcial Sebode, et al.
Journal of Hepatology|December 3, 2014
Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitisJohannes Hartl, Hanno Ehlken, Christina Weiler-Normann, et al.
Der Internist|September 21, 2021
[Severe secondary sclerosing cholangitis as manifestation of a very rare underlying disease]Britta Franziska Zecher, Roman Zenouzi, Melanie Lang, et al.
Journal of Hepatology|November 29, 2017
Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitisJohannes Hartl, Hanno Ehlken, Marcial Sebode, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 21, 2021
Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcomeMartin Reike-Kunze, Roman Zenouzi, Johannes Hartel, et al.
Alimentary Pharmacology & Therapeutics|May 9, 2020
A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitisTimur Liwinski, Christian Casar, Malte C Ruehlemann, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
<i>Quo vadis</i> autoimmune hepatitis? - Summary of the 5<sup>th</sup> international autoimmune hepatitis group research workshop 2024Bastian Engel, David N Assis, Mamatha Bhat, et al.
Pageof 10